Dizal (Jiangsu) Pharmaceutical Co., Ltd.

XSSC:688192 Stock Report

Market Cap: CN¥18.7b

Dizal (Jiangsu) Pharmaceutical Future Growth

Future criteria checks 2/6

Dizal (Jiangsu) Pharmaceutical is forecast to grow earnings and revenue by 58.9% and 45.1% per annum respectively while EPS is expected to grow by 59.1% per annum.

Key information

58.9%

Earnings growth rate

59.1%

EPS growth rate

Biotechs earnings growth43.4%
Revenue growth rate45.1%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

XSSC:688192 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,835-73-40755
12/31/2025947-561-648-4905
12/31/2024456-858-1,053-8265
9/30/2024390-837-862-762N/A
6/30/2024295-938-869-829N/A
3/31/2024173-1,092-929-891N/A
12/31/202391-1,108-1,000-968N/A
9/30/202340-1,055-885-851N/A
6/30/2023N/A-905-801-763N/A
3/31/2023N/A-794-714-634N/A
12/31/2022N/A-736-677-603N/A
9/30/20224-714-648-575N/A
6/30/20227-716-600-532N/A
3/31/202210-716-549-537N/A
12/31/202110-670-501-492N/A
9/30/202111-593-434-429N/A
12/31/202028-587-622-410N/A
12/31/201941-446-379-366N/A
12/31/201839-174-149-136N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688192 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 688192 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 688192 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 688192's revenue (45.1% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 688192's revenue (45.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 688192's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y